Combined Dehydropeiandrosterone and Growth Hormone in Women With Expected Poor Ovarian Response Undergoing ICSI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

230 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Two hundred and thirty women with expected poor ovarian response undergoing IVF/ICSI will be randomly divided into 2 equal groups using computer generated random numbers. Group 1 will receive DHEA 25 mg (DHEA 25mg, Natrol , USA) t.d.s for 12 weeks before starting IVF/ICSI cycle in addition to Growth hormone (GH; Somatotropin, Sedico, Egypt) 4 IU on day 6 of human menopausal gonadotropin (hMG) stimulation in a daily dose of 2.5 mg subcutaneous (sc) until the day of human chorionic gonadotropin (hCG) triggering Group 2 will receive an oral placebo t.d.s. daily for 12 weeks before ICSI in addition to a sc placebo similar to GH daily from day 6 of stimulation until the day of hCG trigger.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian Response

NCT02736591

Subfertility

UNKNOWN PHASE3

Effect of GH Administration in Poor Responders Undergoing Intracytoplasmic Sperm Injection (ICSI)

NCT05281341

Female Infertility

COMPLETED PHASE4

The Effect of Pretreatment With Dydrogesterone Vs Combined Estradiol Valerate and Dydrogestrone on Clinical Pregnancy Outcome of ICSI in PCOS Patients"

NCT05300841

PCOS ICSI

UNKNOWN EARLY_PHASE1

Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist in With Expected High Ovarian Response Undergoing in Vitro Fertilization

NCT05951400

IVF PCO

UNKNOWN PHASE2/PHASE3

Effects of Pentoxifylline and Vitamin E on Pregnancy Rate in Infertile Women Treated by ICSI:

NCT03476564

Infertility, Female

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be conducted in Cairo university hospitals and Dar Al-Teb Infertility and Assisted conception center, Giza Egypt. All patients will be evaluated for their expected ovarian response. Patients fulfilling the Bologna criteria definition of poor ovarian response will be invited to participate in the study and to sign informed consent forms.

Two hundred and thirty women with expected poor ovarian response (POR) undergoing IVF/ICSI will be randomly divided into 2 equal groups using computer generated random numbers. Group 1 will receive DHEA 25 mg (DHEA 25mg, Natrol , USA) t.d.s daily for 12 weeks before starting IVF/ICSI cycle in addition to GH Growth hormone (Somatotropin, Sedico, Egypt) 4 IU on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering Group 2 will receive an oral placebo t.d.s. daily for 12 weeks before ICSI in addition to a placebo similar to GH daily from day 6 of stimulation until the day of hCG trigger.

Patients included in the study will be subjected to full history taking and clinical examination. On the second day of menstruation serum FSH, LH, Prolactin and Oestradiol will be assessed and the antral follicular count (AFC) will be assessed using a vaginal ultrasound scan. AFC will be defined as the number of follicles measuring 3-10mm.

All patients will have gonadotropin antagonist protocol with Human menopausal gonadotrophin (HMG) stimulation until the day of (Human chorionic gonadotrophin (HCG) administration. On the second day of menstruation serum FSH, LH, Prolactin and Oestradiol will be assessed and the antral follicular count (AFC) will be assessed using a vaginal ultrasound scan. AFC will be defined as the number of follicles measuring 3-10mm.

The stimulation protocol will start on day 2 using 450-300 IU HMG ( Merional® IBSA, Lugano, Switzerland) and GnRH antagonist, cetrorelix (Cetrotide® Merck Serono, Darmstadt, Germany) 0.025 mg daily. Gonadotropins will be administered for 4 to 5 days, after which the dose will be adjusted according to the ovarian response. The ovarian response will be monitored by transvaginal ultrasound and serum E2 levels. When three or more follicles reached a maximum diameter of 16 mm, highly purified HCG 5000 or 10,000 IU (Choriomon ®IBSA) will be administered. The procedure will be cancelled if less than 3 follicles 16 mm in size are present 12 days after starting gonadotropins despite doses reaching 450 IU. The cycle will be also cancelled if there is risk of ovarian hyperstimulation like massive ovarian enlargement or serum estradiol exceeds 3000pg/L Transvaginal oocyte retrieval will be performed 34-36 h after the administration of HCG. Oocytes will be fertilized either via IVF or ICSI based on the couple's history. Fertilization will be assessed 16-18 h after IVF or ICSI. Embryos will be transferred on Day 3 or 5. Vaginal tablets containing progesterone (Prontogest® IBSA) 400 mg/day will be given when fertilization is confirmed. A pregnancy test will be done 2 weeks after embryo transfer. For patients with a positive pregnancy test, progesterone is to be continued for an additional 4 weeks. Clinical pregnancy will be defined as Visualization of an intrauterine gestational sac 5 weeks after embryo transfer. And ongoing pregnancy will be defined as the sonographic confirmation of fetal heart pulsations at 12 weeks.

Sample size calculation:

The researchers are planning a study of independent cases and controls with 1 control(s) per case. Kotb et al found that the ongoing pregnancy rate in women undergoing IVF/ICSI who received DHEA with expected POR according to the Bologna criteria is 0.285 versus 0.128 in the control group. Assuming that adding GH to DHEA will not increase the ongoing pregnancy rate, the researchers will need to study 103 case patients and 103 control patients to be able to reject the null hypothesis that the exposure rates for case and controls are equal with probability (power) 0.8. The researchers added 12 patients to each arm accounting for any missing data or losses to follow up. The Type I error probability associated with this test of this null hypothesis is 0.05. The researchers used an uncorrected chi-squared statistic to evaluate this null hypothesis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subfertility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

Women will receive oral DHEA 25 mg t.d.s daily for 12 weeks before ICSI in addition to daily GH injections from day 6 of hMG administration until the day of hCG administration.

Group Type ACTIVE_COMPARATOR

DHEA

Intervention Type DRUG

Women will receive oral DHEA 25 mg t.d.s. for 12 weeks before ICSI.

Growth hormone

Intervention Type DRUG

Women will receive GH subcutaneous injections daily from day 6 of hMG administration until the day of hCG administration.

Placebo group

Women will receive an oral placebo similar to DHEA t.d.s daily for 12 weeks before ICSI in addition to daily placebo injections similar to GH from day 6 of hMG administration until the day of hCG administration.

Group Type PLACEBO_COMPARATOR

Placebo 1

Intervention Type DRUG

Women will receive an oral placebo similar to DHEA t.d.s for 12 weeks before ICSI

Placebo 2

Intervention Type DRUG

Women will receive subcutaneous placebo injections similar to GH daily starting from day 6 of hMG injections until the day of hCG injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DHEA

Women will receive oral DHEA 25 mg t.d.s. for 12 weeks before ICSI.

Intervention Type DRUG

Growth hormone

Women will receive GH subcutaneous injections daily from day 6 of hMG administration until the day of hCG administration.

Intervention Type DRUG

Placebo 1

Women will receive an oral placebo similar to DHEA t.d.s for 12 weeks before ICSI

Intervention Type DRUG

Placebo 2

Women will receive subcutaneous placebo injections similar to GH daily starting from day 6 of hMG injections until the day of hCG injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women undergoing ICSI with expected poor ovarian response according to the Bologna criteria

Exclusion Criteria

* Body mass index \>35 Kg/m2.
* Women with a single ovary.
* Allergy to DHEA or GH.
* Diabetic women on insulin as insulin lowers DHEA levels and might reduce its effectiveness

Minimum Eligible Age

20 Years

Maximum Eligible Age

43 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No